{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:29:47Z","timestamp":1791822587934,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-synthetase\u00a0syndrome (ASSD)\u00a0is\u00a0a\u00a0chronic\u00a0autoimmune\u00a0condition\u00a0characterized by antibodies directed against an aminoacycl transfer RNA synthetase (ARS) along with a group of clinical features including the classical clinical triad: inflammatory myopathy, arthritis, and interstitial lung disease (ILD). ASSD is highly heterogenous due to different organ involvement, and ILD is the main cause of mortality and function loss, which presents as different patterns when diagnosed. We designed this retrospective cohort to describe the clinical features and disease behaviour of ASSD associated ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data of 108 cases of ASSD associated ILD were retrospectively collected in Beijing Chaoyang Hospital from December\u00a02017 to March\u00a02019. Data were obtained from the Electronic Medical Record system. Patients were divided into 5 groups according to distinct aminoacyl tRNA synthetase (ARS) antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 108 consecutive patients were recruited. 33 were JO-1 positive, 30 were PL-7 positive, 23 were EJ positive, 13 were PL-12 positive and 9\u00a0were OJ positive. The JO-1  (+) group had a significant higher rate of mechanic\u2019s hand (57.6%) than other 4 groups. Polymyositis\/dermatomyositis (PM\/DM) was diagnosed in 25 (23.1%) patients and no difference was observed among the 5 groups. The PL-7  (+) group had a higher frequency of UIP pattern (13.3%) than the other 4 groups but the difference was not significant, and the EJ (+) group had the most frequent OP pattern (78.2%), which was significantly higher than the PL-7 (+) (P\u2009&lt;\u20090.001) and PL-12 (+) groups (P\u2009=\u20090.025). The median follow-up time was 10.7\u00a0months, during which no patients died. All received prednisone treatment, with or without immunosuppressants. At the 6-month\u00a0follow-up, 96.3% of all patients (104\/108) had a positive response to therapy, the JO-1 (+) and EJ (+) groups had a significantly higher improvement of forced vital capacity than the other 3 groups (P\u2009&lt;\u20090.05), and the PL-7 group had the lowest FVC improvement (P\u2009&lt;\u20090.05). The JO-1 (+) group and EJ (+) group had significantly higher anti-Ro-52\u00a0positive occurrence than the other 3 groups (P\u2009&lt;\u20090.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti PL-7 antibody had the same frequency as anti-JO-1 in ASSD-ILD, in which the ILD pattern was different with distinct anti-ARS antibodies. Most ASSD-ILD had a positive response to steroid therapies, with or without immunosuppressants. The PL-7 (+) group had the highest occurrence of UIP pattern, and a significantly lower response to therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-021-01399-5","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T15:35:32Z","timestamp":1613144132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-7740","authenticated-orcid":false,"given":"Xi","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"6","key":"1399_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138(6):1464\u201374.","journal-title":"Chest"},{"issue":"1","key":"1399_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","volume":"37","author":"J Solomon","year":"2011","unstructured":"Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37(1):100\u20139.","journal-title":"J Bras Pneumol"},{"issue":"7","key":"1399_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, et al. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. J Rheumatol. 2017;44(7):1051\u20137.","journal-title":"J Rheumatol"},{"issue":"8","key":"1399_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11926-013-0349-8","volume":"15","author":"B Hervier","year":"2013","unstructured":"Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep. 2013;15(8):349.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"1399_CR5","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","volume":"8","author":"L Cavagna","year":"2019","unstructured":"Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019;8(11):2013.","journal-title":"J Clin Med."},{"issue":"9","key":"1399_CR6","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3390\/jcm9093033","volume":"9","author":"G Dei","year":"2020","unstructured":"Dei G, Rebora P, Catalano M, Sebastiani M, Faverio P, Pozzi MR, et al. Functional progression in patients with interstitial lung disease resulted positive to antisynthetase antibodies: a multicenter, retrospective analysis. J Clin Med. 2020;9(9):3033.","journal-title":"J Clin Med."},{"issue":"9","key":"1399_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1399_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"1399_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"282","key":"1399_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","volume":"77","author":"C Marguerie","year":"1990","unstructured":"Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019\u201338.","journal-title":"Q J Med"},{"issue":"6","key":"1399_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/BOR.0000000000000434","volume":"29","author":"S Monti","year":"2017","unstructured":"Monti S, Montecucco C, Cavagna L. Clinical spectrum of anti-Jo-1-associated disease. Curr Opin Rheumatol. 2017;29(6):612\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"1399_CR12","doi-asserted-by":"publisher","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Y Hamaguchi","year":"2013","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE. 2013;8(4):e60442.","journal-title":"PLoS ONE"},{"issue":"136","key":"1399_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1183\/16000617.00002015","volume":"24","author":"JC Lega","year":"2015","unstructured":"Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015;24(136):216\u201338.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"1399_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/08916930600622884","volume":"39","author":"H Yoshifuji","year":"2006","unstructured":"Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):233\u201341.","journal-title":"Autoimmunity"},{"issue":"6","key":"1399_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10794","volume":"47","author":"I Marie","year":"2002","unstructured":"Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614\u201322.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1399_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","volume":"18","author":"T Barba","year":"2019","unstructured":"Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(2):113\u201322.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1399_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976\u201387.","journal-title":"Eur Respir J"},{"issue":"18","key":"1399_CR18","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"1399_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1399_CR20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","volume":"108","author":"C Johnson","year":"2014","unstructured":"Johnson C, Connors GR, Oaks J, Han S, Truong A, Richardson B, et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med. 2014;108(10):1542\u20138.","journal-title":"Respir Med"},{"issue":"9","key":"1399_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","volume":"34","author":"J Rojas-Serrano","year":"2015","unstructured":"Rojas-Serrano J, Herrera-Bringas D, Mejia M, Rivero H, Mateos-Toledo H, Figueroa JE. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD). Clin Rheumatol. 2015;34(9):1563\u20139.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"1399_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11(10):739\u201345.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1399_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.humpath.2014.01.018","volume":"45","author":"SA Yousem","year":"2014","unstructured":"Yousem SA, Schneider F, Bi D, Oddis CV, Gibson K, Aggarwal R. The pulmonary histopathologic manifestations of the anti-PL7\/antithreonyl transfer RNA synthetase syndrome. Hum Pathol. 2014;45(6):1199\u2013204.","journal-title":"Hum Pathol"},{"issue":"6","key":"1399_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/modpathol.2010.65","volume":"23","author":"SA Yousem","year":"2010","unstructured":"Yousem SA, Gibson K, Kaminski N, Oddis CV, Ascherman DP. The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod Pathol. 2010;23(6):874\u201380.","journal-title":"Mod Pathol"},{"issue":"3","key":"1399_CR25","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1183\/09031936.00104310","volume":"37","author":"B Hervier","year":"2011","unstructured":"Hervier B, Uzunhan Y, Hachulla E, Benveniste O, Nunes H, Delaval P, et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J. 2011;37(3):714\u20137.","journal-title":"Eur Respir J"},{"issue":"4","key":"1399_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/MD.0b013e318260977c","volume":"91","author":"A Labirua-Iturburu","year":"2012","unstructured":"Labirua-Iturburu A, Selva-O\u2019Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012;91(4):206\u201311.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1399_CR27","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/rheumatology\/kep455","volume":"49","author":"B Hervier","year":"2010","unstructured":"Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49(5):972\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1399_CR28","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1378\/chest.08-2233","volume":"135","author":"M Kalluri","year":"2009","unstructured":"Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al. Clinical profile of anti-PL-12 autoantibody Cohort study and review of the literature. Chest. 2009;135(6):1550\u20136.","journal-title":"Chest"},{"issue":"6","key":"1399_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"1399_CR30","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"1399_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","volume":"20","author":"CA Mecoli","year":"2018","unstructured":"Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):27.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"1399_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","volume":"46","author":"E Trallero-Araguas","year":"2016","unstructured":"Trallero-Araguas E, Grau-Junyent JM, Labirua-Iturburu A, Garcia-Hernandez FJ, Monteagudo-Jimenez M, Fraile-Rodriguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum. 2016;46(2):225\u201331.","journal-title":"Semin Arthritis Rheum"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01399-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-021-01399-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01399-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T15:37:06Z","timestamp":1613144226000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01399-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01399-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-50724\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-50724\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-50724\/v3","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Waived by the IRB (Institutional Review Board) of Beijing Chaoyang Hospital, because it was a retrospective analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}